Welcome to our dedicated page for enGene Therapeutics news (Ticker: ENGN), a resource for investors and traders seeking the latest updates and insights on enGene Therapeutics stock.
enGene Holdings Inc. (NASDAQ: ENGN) is a clinical-stage, non-viral genetic medicines company whose news flow centers on its lead investigational therapy, detalimogene voraplasmid, for high-risk non-muscle invasive bladder cancer (NMIBC). Company announcements frequently highlight clinical data from the ongoing Phase 2 LEGEND trial, regulatory interactions, and manufacturing readiness for this novel bladder-instilled genetic medicine.
Investors following ENGN news can expect updates on preliminary efficacy and safety results from the LEGEND pivotal cohort and additional cohorts, including complete response rates at various time points and treatment-related adverse event profiles. enGene also reports on changes to trial endpoints following discussions with the U.S. Food and Drug Administration, as well as participation in programs such as the FDA’s Chemistry, Manufacturing, and Controls Development and Readiness Pilot (CDRP) Program.
News releases regularly cover capital markets activities, such as underwritten public offerings of common shares and pre-funded warrants, along with liquidity updates and financial results. Governance and leadership developments, including the appointment of new board members and the hiring of a Chief Medical Officer with extensive bladder cancer experience, are also disclosed through company press releases and related Form 8-K filings.
Because detalimogene has received Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations, regulatory and clinical milestones are key themes in enGene’s communications. For users tracking ENGN, this news page aggregates company-issued updates on clinical progress, FDA designations and programs, financing transactions, and corporate governance developments, offering a centralized view of material events that may shape the company’s development trajectory.
enGene (Nasdaq: ENGN) reported preliminary Phase 2 LEGEND pivotal-cohort data for detalimogene in high-risk, BCG-unresponsive NMIBC with CIS on November 11, 2025. Key interim results include a 63% complete response (CR) rate any time (N=62), 56% CR at 3 months (N=62), and 62% CR at 6 months (N=37). The Company completed pivotal enrollment at 125 patients, exceeding target by 25%.
Safety was favorable: 42% experienced a treatment-related adverse event (mainly Grade 1/2), 1.6% had dose interruptions, and 0.8% discontinued for TRAEs. enGene plans a BLA filing in H2 2026 with potential approval in 2027.
enGene (Nasdaq: ENGN) will host a live conference call and webcast on November 11, 2025 at 8:00 a.m. ET to present new preliminary data from the pivotal cohort of the ongoing LEGEND trial for detalimogene voraplasmid in high‑risk, BCG‑unresponsive non‑muscle invasive bladder cancer with carcinoma in situ.
Registration is required to receive dial‑in details; a live webcast link and a slide deck (posted ~30 minutes before the call) will be available on the company’s Events and Presentations page. A replay of the webcast will be accessible on the company website for one year.
enGene (Nasdaq: ENGN) announced management will participate in three investor conferences in November 2025: Guggenheim 2nd Annual Healthcare Innovation Conference on Nov 11, 2025 at 12:30 p.m. ET, Stifel 2025 Healthcare Conference on Nov 12, 2025 at 2:00 p.m. ET, and Jefferies Global Healthcare Conference in London on Nov 18, 2025 at 8:30 a.m. GMT / 3:30 a.m. ET.
A live webcast of all presentations will be accessible in the Investors section of enGene's website and archived there for 90 days.
enGene (Nasdaq: ENGN) was named to BioSpace’s 2026 Best Places to Work, one of 50 U.S. life‑science employers recognized for culture, career growth and innovation.
The company highlights its mission to advance non‑viral genetic medicines, specifically its late‑stage gene therapy detalimogene voraplasmid (detalimogene, previously EG‑70), being studied in the multi‑cohort Phase 2 LEGEND trial including a pivotal cohort for high‑risk, BCG‑unresponsive, non‑muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS).
This award follows enGene’s June selection as BIOTECanada’s 2025 Biotech Company of the Year, and the company cites the recognition as affirming its purpose‑driven culture and talent attraction efforts.
enGene Holdings (NASDAQ: ENGN), a clinical-stage non-viral genetic medicines company, has announced inducement equity awards for four new employees, including Chief Medical Officer Hussein Sweiti, M.D., MSc. The grants were made on September 30, 2025.
Dr. Sweiti received options to purchase 600,000 common shares, while three other employees received options for 57,950 shares. All options have an exercise price of $6.83 per share, matching the closing price on the grant date. The options have a 10-year term with a four-year vesting schedule: 25% after one year and the remainder vesting monthly over three years.
enGene Holdings (NASDAQ: ENGN) has appointed Dr. Hussein Sweiti as Chief Medical Officer, effective September 29, 2025. Dr. Sweiti, a surgical oncologist with over 15 years of experience, joins from Johnson & Johnson where he was Global Medical Head of Oncology Clinical Development and played a key role in securing FDA approval for a bladder cancer treatment.
Dr. Sweiti will oversee enGene's global clinical development strategy for detalimogene, their lead candidate for non-muscle invasive bladder cancer (NMIBC). His appointment comes at a crucial time as enGene prepares for a planned BLA submission in the second half of 2026, following the completion of target enrollment in detalimogene's pivotal NMIBC clinical trial.
enGene Holdings (NASDAQ:ENGN) reported key milestones and financial results for Q3 2025. The company achieved target enrollment of 100 patients for the pivotal cohort of its LEGEND trial studying detalimogene in high-risk BCG-unresponsive NMIBC. The FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to detalimogene voraplasmid, providing regulatory advantages including potential rolling submission and priority review.
Financial highlights include $224.9 million in cash and marketable securities, providing runway into 2027. Q3 operating expenses increased to $29.9 million, with a net loss of $0.57 per share. The company plans to provide LEGEND trial data updates in Q4 2025 and submit a BLA filing in 2H 2026.
enGene Holdings (NASDAQ:ENGN) has reached a significant milestone in its LEGEND Phase 2 trial for detalimogene voraplasmid, achieving the target enrollment of 100 patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in-situ (CIS).
The company plans to overenroll in its pivotal cohort and has adjusted its timeline for Biologic License Application (BLA) submission to 2H 2026. An update from the LEGEND trial's pivotal cohort is expected in Q4 2025. The trial aims to develop the first non-viral gene therapy for NMIBC, focusing on balancing efficacy, safety, and ease of use.
enGene Holdings (Nasdaq: ENGN), a clinical-stage non-viral gene therapy company, has announced its participation in three major healthcare investor conferences in September 2025. The company will present at the Wells Fargo Healthcare Conference on September 3 at 8:45 a.m. ET, the H.C. Wainwright Global Investment Conference on September 8 at 1:30 p.m. ET, and the Morgan Stanley Global Healthcare Conference on September 10 at 1:50 p.m. ET.
All presentations will be available via webcast on the company's website under the "Investors" section and will remain accessible for 90 days following the events.
enGene Holdings (NASDAQ: ENGN), a clinical-stage non-viral gene-based immunotherapy company, has granted inducement equity awards to three new employees effective July 31, 2025. The awards include non-qualified stock options to purchase 93,200 common shares at an exercise price of $3.79 per share.
The stock options have a 10-year term and will vest over four years, with 25% vesting after one year and the remainder vesting monthly over three years. These grants were approved by the independent Compensation Committee as employment inducements under NASDAQ Rule 5635(c)(4).